Catalent prices IPO at $20.50, midpoint of the range

By
A A A

Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, raised $871 million by offering 42.5 million shares (100% primary) at $20.50, the midpoint of the $19-$22 range. At its offer price, Catalent commands a market cap of $2.5 billion and an EV of $4.4 billion. Catalent will list on the NYSE under the symbol CTLT. Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman Sachs, Jefferies & Co. and Deutsche Bank all acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CTLT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Finding Heart in an Organ
Finding Heart in an Organ           

Stocks

Referenced

100%

Most Active by Volume

113,378,902
  • $16.79 ▲ 1.33%
89,763,454
  • $7 ▲ 6.54%
67,512,111
  • $42.88 ▲ 3.93%
60,846,215
  • $101.66 ▲ 0.23%
52,286,887
  • $16.38 ▼ 7.09%
42,129,258
  • $52.19 ▲ 2.98%
36,281,096
  • $46.695 ▼ 0.65%
31,634,172
  • $25.16 ▼ 0.08%
As of 9/12/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com